Zomedica Q3 revenue $4.78M, net loss $5.0M; cash $158.5M

Zomedica Corp.

2022-Q3 EPS reported -$0.01 revenue$12,773,000

Total revenue $4.78M (vs $0.02M Q3 2021); gross margin 75%.
Net loss $5.0M ($0.005/shr) vs $6.35M loss prior year.
Cash, equivalents, and AFS securities $158.5M at Sep 30, 2022.
Closed acquisitions of Revo 2 imaging assets and Assisi LOOP/Calmer Canine product lines.
PulseVet small animal unit sales up 225% YoY; TRUFORMA revenue up 350% YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zomedica Corp. reported the three months ended September 30, 2022 results: revenue $4.78 million, net income $5.00 million, EPS $0.005 per share.

Period: the three months ended September 30, 2022
Revenue: $4.78 million
Net income: $5.00 million
EPS: $0.005 per share
Result: reported results

Exact text from the filing

Summary Third Quarter 2022 Results Zomedica reported a net loss for the three months ended September 30, 2022, of $5.00 million, or $0.005 per share, compared to a net loss of $6.35 million, or $0.006 per share, for the three months ended September 30, 2021, a decrease in losses of $1.35 million or approximately 21%. Zomedica reported a net loss for the nine months ended September 30, 2022, of $14.21 million, or $0.014 per share, compared to a net loss of $15.09 million, or $0.050 per share, after adjustments for equity charges, for the nine months ended September 30, 2021, a decrease in losses of $0.88 million or approximately 6%. Revenue for the three months ended September 30, 2022, was $4.78 million, compared to $0.02 million for the three months ended September 30, 2021, an increase of $4.76 million or approximately 23,800%.

View on SEC.gov

Browse all earnings releases →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-22-015279

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.